These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 31380588

  • 1. Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naïve chronic hepatitis B patients.
    Zhang Q, Li G, Yu Y, Qiu C, Zheng J, Zhang H, Zhang M, Song Z, Yang Y, Du X, Hong J, Lu J, Li N, Tang Q, Xu L, Wang X, Huang Y, Zhang J, Chen Z, Zhang W.
    J Viral Hepat; 2019 Jul; 26 Suppl 1():59-68. PubMed ID: 31380588
    [Abstract] [Full Text] [Related]

  • 2. Histological responses of peginterferon alpha add-on therapy in patients with chronic hepatitis B with advanced liver fibrosis after long-term nucleos(t)ide analog treatment.
    Li G, Zhang Q, Yu Y, Qiu C, Zhang H, Zhang M, Song Z, Yang Y, Hong J, Lu J, Li N, Tang Q, Xu L, Wang X, Zhang W, Chen Z.
    J Viral Hepat; 2019 Jul; 26 Suppl 1():50-58. PubMed ID: 31380590
    [Abstract] [Full Text] [Related]

  • 3. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT, Ye XG, Zhou XY.
    World J Gastroenterol; 2016 Dec 14; 22(46):10210-10218. PubMed ID: 28028369
    [Abstract] [Full Text] [Related]

  • 4. Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B.
    Liu Y, Li H, Yan X, Wei J.
    J Viral Hepat; 2019 Jul 14; 26 Suppl 1():69-76. PubMed ID: 31380585
    [Abstract] [Full Text] [Related]

  • 5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J, Jones J, Takeda A, Davidson P, Price A.
    Health Technol Assess; 2006 Aug 14; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [Abstract] [Full Text] [Related]

  • 6. Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patient with a poor virological response to peginterferon alfa.
    Wang YX, Zheng SM, Zhang Y, Qin JP, Lin H, Liu XC, Shen CF, Jiang MD.
    Scand J Gastroenterol; 2013 Feb 14; 48(2):213-7. PubMed ID: 23234601
    [Abstract] [Full Text] [Related]

  • 7. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON).
    Chi H, Hansen BE, Guo S, Zhang NP, Qi X, Chen L, Guo Q, Arends P, Wang JY, Verhey E, de Knegt RJ, Xie Q, Janssen HLA.
    J Infect Dis; 2017 Apr 01; 215(7):1085-1093. PubMed ID: 28329061
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
    Kim BH, Lee YJ, Kim W, Yoon JH, Jung EU, Park SJ, Kim YJ, Lee HS.
    Scand J Gastroenterol; 2012 Sep 01; 47(8-9):1048-55. PubMed ID: 22726105
    [Abstract] [Full Text] [Related]

  • 9. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.
    Sun J, Ding H, Chen G, Wang G, Wei L, Zhang J, Xie Q, Wan M, Tang H, Chen S, Gao Z, Wang Y, Zhang D, Huang W, Sheng J, Ning Q, Yang D, Lu J, Pan C, Yang Y, Wang J, Sun C, Wang Q, Hou J.
    BMC Gastroenterol; 2019 May 02; 19(1):65. PubMed ID: 31046700
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, Nosotti L, Mari T, De Santis A, Ponti ML, Sorbello O, Iacomi F, Angelico M.
    Antivir Ther; 2009 May 02; 14(8):1165-74. PubMed ID: 20032546
    [Abstract] [Full Text] [Related]

  • 11. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-Alias M, Carrat F, ANRS HB06 PEGAN Study Group.
    Lancet Gastroenterol Hepatol; 2017 Mar 02; 2(3):177-188. PubMed ID: 28404133
    [Abstract] [Full Text] [Related]

  • 12. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
    Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY.
    J Dig Dis; 2013 Aug 02; 14(8):446-50. PubMed ID: 23615131
    [Abstract] [Full Text] [Related]

  • 13. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W, Yuan H, Mao XR, Deng YD, Chen L.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar 02; 21(3):184-8. PubMed ID: 23967738
    [Abstract] [Full Text] [Related]

  • 14. Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure.
    Weng M, Zeng WZ, Wu XL, Zhang Y, Jiang MD, Wang Z, Zhou DJ, He X.
    Virol J; 2013 Sep 06; 10():277. PubMed ID: 24010768
    [Abstract] [Full Text] [Related]

  • 15. A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis.
    Wei W, Wu Q, Zhou J, Kong Y, You H.
    Int J Environ Res Public Health; 2015 Aug 21; 12(8):10039-55. PubMed ID: 26308024
    [Abstract] [Full Text] [Related]

  • 16. Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs.
    Huang J, Zhang K, Chen W, Liao J, Luo X, Chen R.
    Sci Rep; 2017 Oct 17; 7(1):13383. PubMed ID: 29042662
    [Abstract] [Full Text] [Related]

  • 17. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.
    van Zonneveld M, Zondervan PE, Cakaloglu Y, Simon C, Akarca US, So TM, Flink HJ, de Man RA, Schalm SW, Janssen HL, HBV 99-01 Study Group.
    Liver Int; 2006 May 17; 26(4):399-405. PubMed ID: 16629642
    [Abstract] [Full Text] [Related]

  • 18. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
    Xu Y, Wang X, Liu Z, Zhou C, Qi W, Jiao J, Yu F, Guo H, Zhao P, Wang J.
    BMC Gastroenterol; 2017 Aug 30; 17(1):102. PubMed ID: 28854883
    [Abstract] [Full Text] [Related]

  • 19. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
    Boglione L, Cusato J, Allegra S, Esposito I, Patti F, Cariti G, Di Perri G, D'Avolio A.
    Antiviral Res; 2014 Feb 30; 102():35-43. PubMed ID: 24316030
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.
    Ratnam D, Dev A, Nguyen T, Sundararajan V, Harley H, Cheng W, Lee A, Rusli F, Chen R, Bell S, Pianko S, Sievert W.
    J Gastroenterol Hepatol; 2012 Sep 30; 27(9):1447-53. PubMed ID: 22168789
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.